122 related articles for article (PubMed ID: 9173120)
1. [The initial experience of using fraxiparin in extracorporeal detoxication in clinical cardiology].
Sirenko IuN; Sychev OS; Reĭko MN; Shchupak MB; Sidorenko PI
Klin Khir (1962); 1994; (12):23-5. PubMed ID: 9173120
[TBL] [Abstract][Full Text] [Related]
2. [The experience of fraxiparin application in urgent surgery].
Khizhniak AA; Trushkina TV
Klin Khir; 2000; (1):26-9. PubMed ID: 10859916
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
Nurmohamed MT; van Riel AM; Henkens CM; Koopman MM; Que GT; d'Azemar P; Büller HR; ten Cate JW; Hoek JA; van der Meer J; van der Heul C; Turpie AG; Haley S; Sicurella A; Gent M
Thromb Haemost; 1996 Feb; 75(2):233-8. PubMed ID: 8815566
[TBL] [Abstract][Full Text] [Related]
4. Immediate type hypersensitivity after injection of nadroparin (Fraxiparin).
Bekkenk MW; van Zuuren EJ
Thromb Haemost; 2005 Sep; 94(3):673-4. PubMed ID: 16268488
[No Abstract] [Full Text] [Related]
5. [Extracorporeal methods for detoxification in the combined treatment of gunshot peritonitis].
Sychev MD; Manucharov NK; Tomaev KB; Litvin AA
Voen Med Zh; 1992 Jan; (1):44-5. PubMed ID: 1570696
[TBL] [Abstract][Full Text] [Related]
6. [Use of the low-molecular heparin, Fraxiparine, during hemodialysis].
Monhart V; Petrů K
Cas Lek Cesk; 1998 Jan; 137(1):18-21. PubMed ID: 9511272
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
[TBL] [Abstract][Full Text] [Related]
8. [Prophylaxis of thromboembolic complications in bariatric surgery].
Lavrik AS; Tyvonchuk AS; Bubalo AF; Zgonnik AIu
Klin Khir; 2007 Aug; (8):39-42. PubMed ID: 18318070
[TBL] [Abstract][Full Text] [Related]
9. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.
ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW
Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229
[TBL] [Abstract][Full Text] [Related]
10. [The use of extracorporeal detoxication methods in treating infectious disease patients].
Ivanov KS; Gurevich KIa; Shvedov AK
Voen Med Zh; 1992; (4-5):74-7. PubMed ID: 1523824
[TBL] [Abstract][Full Text] [Related]
11. [Antithrombotic properties of heparin independent of its anticoagulant activity].
Krupiński K; Bielawiec M; Breddin HK
Acta Haematol Pol; 1994; 25(3):243-51. PubMed ID: 7992597
[TBL] [Abstract][Full Text] [Related]
12. The in vitro effect of a low molecular weight heparin, nadroparin (Fraxiparine), on leukocytes obtained from patients with vascular diseases.
Neagu M; Manda G; Constantin C; Tanaseanu C; Mikhailidis DP
Int Angiol; 2001 Jun; 20(2):164-73. PubMed ID: 11533525
[TBL] [Abstract][Full Text] [Related]
13. [The prevention of the hemorrhagic and pulmonary complications of extracorporeal detoxification in the multiple organ failure syndrome].
Sadchikov DV; Mil'tsyn AS; Nasekin VA; Osipova OV
Vestn Khir Im I I Grek; 1996; 155(2):79-81. PubMed ID: 8966918
[TBL] [Abstract][Full Text] [Related]
14. [Significance of heparin elimination from plasma in the assessment of coagulogram and antithrombin III activity].
Momot AP; Sokolov EA; Tseĭmakh IIa
Klin Lab Diagn; 1995; (5):31-4. PubMed ID: 7582773
[TBL] [Abstract][Full Text] [Related]
15. [Position of Experts Panel of the Polish Gynecological Society in the application of low molecular weight heparin - nadroparin calcium (Fraxiparine) in obstetrics and gynecology].
Bednarek W; Karowicz-Bilińska A; Kotarski J; Nowak-Markwitz E; Oszukowski P; Paszkowski T; Poreba R; Spaczyński M; Teliga-Czajkowska J;
Ginekol Pol; 2011 Mar; 82(3):230-3. PubMed ID: 21735692
[No Abstract] [Full Text] [Related]
16. Clinical safety and anticoagulation efficacy of low-molecular-weight heparins in chronic hemodialysis patients: a single medical center experience.
Chuang FR; Chen TC; Lee CH; Ng HY; Wang IK; Chang HW; Chuang PH; Wu CH; Yang CC; Su YJ
Ren Fail; 2011; 33(10):990-7. PubMed ID: 22013932
[TBL] [Abstract][Full Text] [Related]
17. [The effect of long-term Fraxiparin treatment on hemostasis in patients with primary pulmonary hypertension].
Chazova IE; Panchenko EP; Dobrovol'skiĭ AB; Nakonechnikov SN; Titaeva EV; Baklanova NA; Belenkov IuN
Ter Arkh; 1997; 69(9):62-6. PubMed ID: 9411832
[TBL] [Abstract][Full Text] [Related]
18. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
[TBL] [Abstract][Full Text] [Related]
19. Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use.
Luzzatto G; Cordiano I; Patrassi G; Fabris F
Thromb Haemost; 1996 Jan; 75(1):211-2. PubMed ID: 8713803
[No Abstract] [Full Text] [Related]
20. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
